Crispact® is a food supplement containing Lactobacillus crispatus M247.
Clinical studies demonstrated that Crispact® promotes the clearance of HPV infection, showing that 71% of HPV-positive women could test negative for HPV after just 3 months of treatment with Crispact®. Complementary to this data, it was highlighted that the use of Crispact®, again in HPV-positive women who had also concomitant cervical lesion, increased the normalization of cervical cytology by 50% when compared to untreated women.
L. crispatus M247 colonizes 94% of treated women, as shown by clinical trials, moreover, it can even be taken alongside metronidazole, since it was also found to be insensitive to high concentrations of this antibiotic, which is widely prescribed by gynaecologists.

Scientific reference(s)

Di Pierro F, Criscuolo AA, Dei Giudici A, Senatori R, Sesti F, Ciotti M, Piccione E. Oral administration of Lactobacillus crispatus M247 to papillomavirus-infected women: results of a preliminary, uncontrolled, open trial. Minerva Obstet Gynecol. 2021 Oct;73(5):621-631. doi: 10.23736/S2724-606X.21.04752-7. Epub 2021 Apr 20. PMID: 33876901.

Dellino M, Cascardi E, Laganà AS, Di Vagno G, Malvasi A, Zaccaro R, Maggipinto K, Cazzato G, Scacco S, Tinelli R, De Luca A, Vinciguerra M, Loizzi V, Daniele A, Cicinelli E, Carriero C, Genco CA, Cormio G, Pinto V. Lactobacillus crispatus M247 oral administration: Is it really an effective strategy in the management of papillomavirus-infected women? Infect Agent Cancer. 2022 Oct 21;17(1):53. doi: 10.1186/s13027-022-00465-9. PMID: 36271433; PMCID: PMC9587645.

Bertuccioli A, Cardinali M, Zonzini G, Cazzaniga M, Di Pierro F. Lactobacillus crispatus M247: Characteristics of a Precision Probiotic Instrument for Gynecological and Urinary Well-Being. Microbiology Research. 2022; 13(4):963-971.

Voltan S, Martines D, Elli M, Brun P, Longo S, Porzionato A, Macchi V, D'Incà R, Scarpa M, Palù G, Sturniolo GC, Morelli L, Castagliuolo I. Lactobacillus crispatus M247-derived H2O2 acts as a signal transducing molecule activating peroxisome proliferator activated receptor-gamma in the intestinal mucosa. Gastroenterology. 2008 Oct;135(4):1216-27. doi: 10.1053/j.gastro.2008.07.007. Epub 2008 Jul 9. PMID: 18722375.

Di Pierro F, Bertuccioli A, Sagheddu V, Cattivelli D, Soldi S, Elli M. Antibiotic resistance profile and adhesion properties of Lactobacillus crispatus M247. Nutrafoods (2019) 2 89-94. DOI 10.17470/NF-019-0012.

Di Pierro F, Bertuccioli A, Cattivelli D, Soldi S, Elli M. Lactobacillus crispatus M247: a possible tool to counteract CST IV. Nutrafoods (2018) 17:169-172DOI 10.17470/NF-018-0001-4.

Additional info

Therapeutical area(s)

Women health · Urogenital system


Antipathogenic activity · Vaginal candidiasis



Dosage form



20 billion(s)

Take full advantage of MicrobiomePost's features